GlassScriptPhysician profile
Georgeanne E Cornell
NPI 1811552029
$3,425.58
in general payments reported to CMS, 2019-2025
15 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2021: $330 · 2022: $738 · 2023: $575 · 2024: $1,415 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,147 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,146.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $618.58 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $498.45 | 2019-2024 | Sotyktu |
| Ucb, INC. | $465.27 | 2022-2025 | Bimzelx |
| Janssen Biotech, INC. | $371.59 | 2024 | Tremfya |
| Dermavant Sciences, INC. | $360.27 | 2023-2024 | Vtama |
| Abbvie INC. | $213.82 | 2022-2024 | |
| Lilly USA, LLC | $165.72 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $121.82 | 2023 | |
| Janssen Scientific Affairs, LLC | $120.63 | 2024 | Tremfya |
| Pfizer INC. | $119.79 | 2024 | |
| Sun Pharmaceutical Industries INC. | $117.46 | 2024 | |
| Krystal Biotech INC | $98.85 | 2023 | Vyjuvek |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Incyte Corporation | $47.56 | 2023-2024 | Opzelura |
| Leo Pharma INC. | $25.78 | 2023 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgeanne Cornell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.